Assets
(8 total)
8Total Assets
0Approved
7Phase 3 / Filed
1Phase 1–2 / Early
8Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
AcellbiaNo recent activity | Phase 3 | CD20Monoclonal antibody | Rheumatoid Arthritis |
| Phase 3 | CD38Monoclonal antibody | Multiple Myeloma | |
| Phase 3 | CD20Monoclonal antibody | Multiple Sclerosis | |
Divozilimab(Ivlizi) | Phase 3 | CD20Monoclonal antibody | Systemic Lupus ErythematosusMultiple SclerosisSystemic Sclerosis |
Levilimab(Ilsira) | Phase 3 | IL-6 receptorMonoclonal antibody | Rheumatoid ArthritisCOVID-19 |
| Phase 3 | IL-17Monoclonal antibody | Psoriatic ArthritisPsoriasis | |
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 1 | BDCA2 (CLEC4C)Monoclonal antibody | Systemic Lupus Erythematosus |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
No financial reports recorded.